Evidence map›Paper›PMID 42293396›Full record

ArticleMaterials today. Bio2026

Polyelectrolyte nanoparticles enable intracellular delivery of STING protein fragments for ovarian cancer immunotherapy.

Justin A Kaskow, Altaf Bacchus, Victoria F Gomerdinger, Adam G Berger, Ze-Hua Li, Thomas J Gerton, Mellany A Smith, Andrea Li, Julia Treese, Aidan Kindopp and 3 more

Abstract read
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Justin A KaskowDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Altaf BacchusDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Victoria F GomerdingerDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Adam G BergerDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ze-Hua LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Thomas J GertonDivision of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mellany A SmithDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Andrea LiDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Julia TreeseDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Aidan KindoppDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Daniela M DinulescuDivision of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Paula T HammondDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Controlled release of RNA-targeting therapy to promote healing of diabetic ulcersF30DK130564 · NIDDK · HARVARD MEDICAL SCHOOL · PI BERGER, ADAM G · 2021 to 2025
$257k
NIDDK NIH HHS F30 DK130564NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Therapeutic activation of stimulator of interferon genes (STING) signaling shows promise as a method of inflaming the tumor microenvironment to generate an anti-cancer immune response. Frequent loss of STING expression in many human cancers renders small-molecule agonists ineffective in cancer cells. We previously demonstrated that delivering a fragment of the STING protein, dubbed STINGΔTM, to the cytosol can bypass this challenge by directly activating downstream signaling molecules in the cytosol; however, this strategy requires an effective cytosolic protein delivery vehicle to be therapeutically active. In this work, we develop a poly(β-amino ester) (PBAE) degradable polycation nanoparticle formulation to target ovarian cancer and deliver bioactive STINGΔTM protein to the cytosol. Screening experiments reveal that increasing PBAE hydrophobicity enables efficient protein encapsulation and delivery to the cytosol. We then develop a pH-shift-mediated method to assemble smaller, negatively charged nanoparticles composed of STINGΔTM protein, PBAE, and a polyanion. The polyanion can tune the cell type specificity of STING signaling activation

Indexed as

CancerImmunotherapyNanoparticlePolyelectrolyteProteinSTING

Identifiers

PMID42293396
PMCPMC13253205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.